Shares of Check Cap Ltd (NASDAQ:CHEK) have been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 12-month consensus price target of $5.00 for the company, according to Zacks. Zacks has also given Check Cap an industry rank of 93 out of 265 based on the ratings given to related companies.
A number of analysts have recently weighed in on CHEK shares. Zacks Investment Research raised Check Cap from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Tuesday, June 14th. Maxim Group raised their price objective on Check Cap from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, August 1st.
Shares of Check Cap (NASDAQ:CHEK) traded up 3.11% during midday trading on Thursday, reaching $1.99. The company had a trading volume of 11,968 shares. The stock’s market capitalization is $24.39 million. Check Cap has a 1-year low of $0.97 and a 1-year high of $3.80. The company’s 50-day moving average is $2.02 and its 200-day moving average is $2.08.
About Check Cap
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap Ltd and related companies with MarketBeat.com's FREE daily email newsletter.